New shot aims to tame hepatitis b virus

NCT ID NCT07519330

Recruiting now Disease control Sponsor: Huahui Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new biologic drug called HH-006 in 45 adults with chronic hepatitis B. Participants receive injections for 48 weeks, and researchers track how well the drug lowers hepatitis B surface antigen (HBsAg) levels. The goal is to see if the drug can control the infection and possibly lead to HBsAg loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HH-006 (a biologic drug given as injection)
What this could lead to: If successful, this could point toward a way to control chronic hepatitis B by lowering or clearing the virus surface antigen, potentially reducing long-term liver damage.
What could go wrong: This is an early Phase II trial with only 45 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS INFECTION

Contacts and locations

Locations

Chongqing University Three Gorges Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.